Making Acidic Cannabinoids Work
Mingowood Pharmacal is set out to stabilize and commercialize acidic cannabinoid compounds like CBDA, THCA, CBGA, and CBCA. Despite the therapeutic promises of these compounds, there were regulatory complexities and manufacturing challenges that they were bound to address.
Mingowood, led by a team of seasoned biotech professionals, had a vision: to unlock the full potential of acidic cannabinoids using their proprietary @LDH™ formulation technology.
The Project Plan
Collaborative Problem Solving
Mingowood needed a way to produce its CBDA formulations cost-effectively and without having to invest in new equipment. To meet those requirements Parimer upgraded their facility’s electrical infrastructure and revamped a lab space to accommodate rented processing equipment all while staying within Mingowood's budget.
Mingowood’s team was invited on-site at Parimer for the first production run, where they worked side-by-side with Parimer’s experts to troubleshoot, share ideas, and even test alternative methods.
Results and Impact
The outcome was successful which included production of stabilized CBDA, in the future will lead to expanding which Mingowood plans to develop into gummies and tablets as a natural anti-inflammatory. Mingowood’s unique @LDH™ technology not only ensures the compound’s stability but also enhances its bioavailability, making it a promising alternative to conventional pain relievers.
With Parimer providing a scalable manufacturing platform without the need for costly infrastructure, Mingowood can stay focused on R&D and commercialization.
What's Next for Mingowood
Mingowood’s goal is to manufacture entirely in the U.S. - sourcing, producing, and scaling domestically. They are also exploring distribution opportunities, both in the U.S. and globally to bring their formulations to a broader market.